Liver function may change how imlunestrant works
NCT ID NCT05440344
First seen Nov 12, 2025 · Last updated Jun 21, 2026 · Updated 26 times
Summary
This completed Phase 1 study looked at how imlunestrant, an oral drug, enters the bloodstream and leaves the body in women with impaired liver function compared to healthy women. 27 female participants took a single dose, and researchers measured drug levels over time. The goal was to understand if liver problems affect drug processing, which could guide future dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
American Research Corporation at Texas Liver Institute
San Antonio, Texas, 78215, United States
-
Inland Empire Liver Foundation
Rialto, California, 92377, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Imlunestrant (oral drug)
What this could lead to
If successful, this study could help doctors determine the right dose of imlunestrant for patients with liver problems.
What could go wrong
This is a very early, small study (27 people) focused on drug levels, not on treating any disease. Results may not apply to men or broader populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.